BiotechTube

sugammadex + Neostigmine + Glycopyrrolate

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade

Trial Timeline

Aug 1, 2016 → Feb 1, 2018

NCT ID
NCT02860507

About sugammadex + Neostigmine + Glycopyrrolate

sugammadex + Neostigmine + Glycopyrrolate is a approved stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT02860507. Target conditions include Neuromuscular Blockade.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT02860507ApprovedCompleted
NCT01479764Phase 3Completed

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
52
Placebo + Sugammadex + Esmeron®MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
85
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
85
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
23
Sugammadex + RocuroniumMerckApproved
85
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
85
neostigmine/glycopyrrolate + sugammadexMerckApproved
85
sugammadexMerckPhase 3
77
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
77
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
85
Sugammadex + NeostigmineMerckApproved
85
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
85
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium Bromide + Rocuronium BromideMerckApproved
85
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
23

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85